Curt I Civin

This inventor holds 26 USPTO granted patents and 13 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Microfluidics Technology. Top assignees: University System of Maryland, Princeton University, Johns Hopkins University. Active years: 1987-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Curt I Civin. Retrieved from https://idiyas.com/inventor/curt-i-civin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 26 (Patent Applications = 13)

% Patents Active = 92.3

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 10)

Average Co-Inventor Count = 2.6

ph-index = 11

Forward Citations = 703(Granted Patents)

Location History:

Towson, MD (US) (2010)
Baltimore, MD (US) (1987 - 2023)

Company Filing History:

15 out of 2,029

University System of Maryland

Johns Hopkins University

Becton Dickinson and Company Limited

patents

7. 1 out of 2,663

University of Pennsylvania

where one patent can have more than one assignee

Years Active: 1987-2026

Loading Chart...

Areas of Expertise:

Microfluidics

Cell Purification

Cancer Treatment

Therapeutically Active Cells

Stem Cells

High Throughput Processing

Artemisinin

BCL-2 Inhibitors

Kinase Inhibitors

Transplantation

Monoclonal Antibodies

Nucleic Acids

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12612597 - Methods for preparing therapeutically active cells using microfluidics (2026-04-28),

2. 12590955 - Methods and systems for processing particles (2026-03-31),

3. 12436081 - Methods and devices for multi-step cell purification and concentration (2025-10-07),

4. 11554105 - Combinations of artemisinins, BCL-2 inhibitors, and kinase inhibitors for cancer treatment (2023-01-17),

5. 11493428 - On-chip microfluidic processing of particles (2022-11-08),

6. 11486802 - Methods and devices for high throughput purification (2022-11-01),

7. 11306288 - Methods for preparing therapeutically active cells using microfluidics (2022-04-19),

8. 11149251 - Methods for preparing therapeutically active cells using microfluidics (2021-10-19),

9. 11142746 - High efficiency microfluidic purification of stem cells to improve transplants (2021-10-12),

10. 10988734 - Methods for preparing therapeutically active cells using microfluidics (2021-04-27),

11. 10976232 - Methods and devices for multi-step cell purification and concentration (2021-04-13),

12. 10852220 - Methods and devices for high throughput purification (2020-12-01),

13. 10844353 - Methods for preparing therapeutically active cells using microfluidics (2020-11-24),

14. 10324011 - Methods and devices for high throughput purification (2019-06-18),

15. 9918972 - Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents (2018-03-20),

Title: Curt I Civin: A Pioneer in Cancer Treatment Innovations

Introduction

Curt I Civin is a notable inventor and researcher based in Baltimore, MD, USA. With a prolific output of 23 patents, he has made significant contributions to the fields of cancer treatment and microfluidic technology, solidifying his reputation as a leader in innovation.

Latest Patents

Civin's latest patents focus on groundbreaking methods for treating cancer, particularly leukemia. One of his notable inventions involves the use of combinations of artemisinins, BCL-2 inhibitors, and kinase inhibitors. The detailed methods showcase how therapeutic amounts of artemisinins, such as artesunate and dihydroartemisinin, can be administered alongside additional agents like BCL-2 inhibitors (e.g., ABT-199) and various kinase inhibitors to enhance treatment efficacy. Furthermore, his work on microfluidic processing devices reveals techniques and systems designed to improve cell quality, streamline workflows, and reduce costs in research and clinical diagnostics for various diseases.

Career Highlights

Civin’s career includes pivotal roles at prestigious institutions such as the University of Maryland and Princeton University. His research work has led to innovative solutions in cancer therapy and biotechnology, establishing him as a key figure in his field. His inventive strategies are crucial for advancing cancer treatment methodologies.

Collaborations

Throughout his career, Curt I Civin has collaborated with esteemed colleagues, including James Christopher Sturm and Robert H. Austin. These partnerships have fostered innovation, enabling the development and refinement of new approaches in cancer treatment and diagnostics.

Conclusion

Curt I Civin's contributions to medical innovation, particularly in cancer treatment and microfluidic technology, highlight his role as a leading inventor. His extensive patent portfolio reflects a commitment to enhancing treatment options and improving clinical outcomes, illustrating the vital impact he has made on science and medicine.

Profile summary based on public USPTO records.